Drugs / L-Tyrosine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Maapliv | — | 2025-07-28 | europa.eu ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable3 trials | ||||||
| — | NCT04518254 | Nov 2021 → Apr 2022 | — | Central Directorate of the Army Health Service | Completed | No outcome recorded |
| — | NCT04549194 | Sep 2020 → Jun 2021 | — | Central Directorate of the Army Health Service | Completed | No outcome recorded |
| — | NCT03845920 | Feb → Sep 2019 | — | Sheffield Hallam University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02035501 Comparator | Jan 2014 → Jan 2015 | nemaline myopathy | Hadassah Medical Organization | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Tyrosine | “Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols.” NCT03845920 ↗ |
| Route | Oral | “per oral route” NCT04518254 ↗ |